Natural Killer (NK) immune cells are essential to human health, performing key roles in surveillance and killing of cancerous and infected cells. Activated NK cells harness and deliver lytic granule-contained, cytotoxic proteins through a specialized area of cell-cell contact (immunological synapse) onto the offending cell. Over the past decade, our laboratory has greatly advanced the understanding of how NK cells use the precisely regulated steps constituting directed secretion to achieve cytotoxic function and control. In this program renewal, we build on our past discoveries to ask critical questions at the root of NK cell biology.
In Aim 1, we ask why multiple pathways to degranulation exist and whether these can be exploited to match specific clinical scenarios. In the previous program, we reported that lytic granules converge to the microtubule organizing center (MTOC) prior to secretion. We hypothesize that convergence focuses an NK cell's killing effect on a single diseased cell (minimizing collateral damage to healthy cells), whereas dispersion promotes wider destruction in environments full of targets. Here, we test these hypotheses using cutting-edge, high- and super- resolution microscopy in conjunction with the only immunologically-dedicated ultrasound guided acoustic trap microscopy (UGATm) cell manipulation system available in the U.S. We will determine whether receptor blocking and/or inhibitors can be used to fine tune convergence to match specific disease contexts like extracellular pathogen infection or advanced cancer.
In Aim 2, we define a new cooperative motility mechanism for degranulation. In the previous program, we discovered that granules are dynamic even after delivery to the synapse, and that degranulation occurs through a nanoscale mesh of actin pores. Here, we define the dynamics and movement mechanisms of both synaptic granules and the actin meshwork using advanced super-resolution microscopy. We hypothesize that these two independent systems utilize dynamics to promote pore finding, efficient degranulation, and ultimately cytotoxicity. This dual-dynamic paradigm would be new to cell biology and would set the stage for therapeutic strategies to enhance NK cell killing by promoting granule access to the synapse. Finally, in Aim 3, we investigate a new role for Vimentin and the intermediate filament (IF) cytoskeleton in the establishment of synapse polarity. Vimentin IF, like synaptic actin, granules, and the MTOC, are dynamic, but intriguingly, they show reverse polarity, localizing to the opposite side of the NK cell. Here, using high-throughput imaging flow cytometry, super-resolution microscopy, inhibitors, and gene targeting, we will test the hypotheses that IF respond to activating signals, establish the distal NK cell pole, and are critical for synapse polarity. This will be the first demonstration of IF as a means to cell polariy. Based on our success in the previous program, we expect the proposed experiments to lead to key insights into directed secretion for NK cell cytotoxicity. We further expect the paradigms that emerge to have broad biological significance and direct applicability to immunological and cell-based therapies.

Public Health Relevance

Natural Killer (NK) immune cells are essential to human health, performing key roles in surveillance and killing of cancerous and infected cells. In this proposal, we study how various NK cell cytoskeletons and motors position and secrete toxic enzymes onto these dangerous cells in a controlled fashion. Better understanding these processes of 'directed secretion' will allow us to precisely manipulate them to promote endogenous NK cell killing, as well as the effectiveness of NK cell immunotherapies for cancer and infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI067946-14
Application #
9670720
Study Section
Innate Immunity and Inflammation Study Section (III)
Program Officer
Lapham, Cheryl K
Project Start
2005-12-01
Project End
2021-03-31
Budget Start
2019-04-01
Budget End
2021-03-31
Support Year
14
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pediatrics
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Gunesch, Justin T; Angelo, Laura S; Mahapatra, Sanjana et al. (2018) Genome-wide analyses and functional profiling of human NK cell lines. Mol Immunol :
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Gwalani, Lavesh A; Orange, Jordan S (2018) Single Degranulations in NK Cells Can Mediate Target Cell Killing. J Immunol 200:3231-3243
Chinn, Ivan K; Eckstein, Olive S; Peckham-Gregory, Erin C et al. (2018) Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood 132:89-100
Carisey, Alexandre F; Mace, Emily M; Saeed, Mezida B et al. (2018) Nanoscale Dynamism of Actin Enables Secretory Function in Cytolytic Cells. Curr Biol 28:489-502.e9
Ruiz-García, Raquel; Vargas-Hernández, Alexander; Chinn, Ivan K et al. (2018) Mutations in PI3K110? cause impaired natural killer cell function partially rescued by rapamycin treatment. J Allergy Clin Immunol 142:605-617.e7
Samaha, Heba; Pignata, Antonella; Fousek, Kristen et al. (2018) A homing system targets therapeutic T cells to brain cancer. Nature 561:331-337
Jacquemet, Guillaume; Paatero, Ilkka; Carisey, Alexandre F et al. (2017) FiloQuant reveals increased filopodia density during breast cancer progression. J Cell Biol 216:3387-3403
Lesteberg, Kelsey; Orange, Jordan; Makedonas, George (2017) Recycling endosomes in human cytotoxic T lymphocytes constitute an auxiliary intracellular trafficking pathway for newly synthesized perforin. Immunol Res 65:1031-1045
Mace, Emily M; Bigley, Venetia; Gunesch, Justin T et al. (2017) Biallelic mutations in IRF8 impair human NK cell maturation and function. J Clin Invest 127:306-320

Showing the most recent 10 out of 69 publications